Marlise R Luskin

58PUBLICATIONS

342CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMolecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (58)

Sort by Publication Date:

|May 26, 2026

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

|May 19, 2026

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

|Mar 30, 2026

Incorporating ALL Biology into Treatment Decisions: Next Steps toward Targeted Therapy in Adult ALL.

Caner Saygin, Matthew T Witkowski, Sinan Cetin

|Feb 26, 2026

Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.

Jonas S Jutzi, Edie Crosse, Chulwoo J Kim

|Feb 24, 2026

Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.

Benjamin Rolles, Cilomar Martins de Oliveira Filho, Nathan Fergusson

|Feb 24, 2026

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

H Moses Murdock, Haesook T Kim, Katie Maurer

Pageof 10

Frequent Collaborators

20 joint publications

Daniel J DeAngelo

19 joint publications

Shai Shimony

18 joint publications

Jacqueline S Garcia

11 joint publications

Eric S Winer

10 joint publications

Evan Chen

9 joint publications

R Coleman Lindsley

7 joint publications

Richard M Stone

6 joint publications

Lori S Muffly